SI3142751T1 - Protitelesa proti-B7-H1 in proti-CTLA-4 za zdravljenje nedrobnoceličnega pljučnega raka - Google Patents
Protitelesa proti-B7-H1 in proti-CTLA-4 za zdravljenje nedrobnoceličnega pljučnega rakaInfo
- Publication number
- SI3142751T1 SI3142751T1 SI201530857T SI201530857T SI3142751T1 SI 3142751 T1 SI3142751 T1 SI 3142751T1 SI 201530857 T SI201530857 T SI 201530857T SI 201530857 T SI201530857 T SI 201530857T SI 3142751 T1 SI3142751 T1 SI 3142751T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ctla
- antibodies
- lung cancer
- small cell
- cell lung
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992658P | 2014-05-13 | 2014-05-13 | |
| US201562105992P | 2015-01-21 | 2015-01-21 | |
| US201562114336P | 2015-02-10 | 2015-02-10 | |
| PCT/EP2015/060523 WO2015173267A1 (en) | 2014-05-13 | 2015-05-12 | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| EP15722195.3A EP3142751B1 (en) | 2014-05-13 | 2015-05-12 | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3142751T1 true SI3142751T1 (sl) | 2019-09-30 |
Family
ID=53175516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530857T SI3142751T1 (sl) | 2014-05-13 | 2015-05-12 | Protitelesa proti-B7-H1 in proti-CTLA-4 za zdravljenje nedrobnoceličnega pljučnega raka |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10232040B2 (sl) |
| EP (2) | EP3142751B1 (sl) |
| JP (4) | JP6648038B2 (sl) |
| KR (4) | KR20230165876A (sl) |
| CN (2) | CN113230398A (sl) |
| AU (3) | AU2015260962B2 (sl) |
| BR (1) | BR122023025321A2 (sl) |
| CA (1) | CA2947471A1 (sl) |
| CY (1) | CY1122642T1 (sl) |
| DK (1) | DK3142751T3 (sl) |
| ES (1) | ES2749098T3 (sl) |
| GB (1) | GB2531094A (sl) |
| HR (1) | HRP20191449T1 (sl) |
| HU (1) | HUE045965T2 (sl) |
| IL (2) | IL248528B (sl) |
| LT (1) | LT3142751T (sl) |
| ME (1) | ME03493B (sl) |
| MX (1) | MX2016014189A (sl) |
| PL (1) | PL3142751T3 (sl) |
| PT (1) | PT3142751T (sl) |
| RS (1) | RS59134B1 (sl) |
| RU (1) | RU2702332C2 (sl) |
| SG (2) | SG10201810108PA (sl) |
| SI (1) | SI3142751T1 (sl) |
| TW (3) | TWI707692B (sl) |
| WO (1) | WO2015173267A1 (sl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2701327C2 (ru) * | 2013-09-11 | 2019-09-25 | Медиммьюн Лимитед | Антитела к b7-h1 для лечения опухолей |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| RU2702332C2 (ru) * | 2014-05-13 | 2019-10-08 | Медиммьюн Лимитед | Антитела к в7-н1 и к ctla-4 для лечения немелкоклеточного рака легкого |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| GB2535256A (en) * | 2014-08-28 | 2016-08-17 | Medimmune Ltd | Combination therapy for PD-L1 negative tumors |
| MY194225A (en) | 2015-03-13 | 2022-11-22 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| SG11201807474SA (en) * | 2016-04-25 | 2018-11-29 | Medimmune Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| JP7241352B2 (ja) * | 2016-05-17 | 2023-03-17 | ジーンセントリック セラピューティクス， インコーポレイテッド | 肺扁平上皮癌のサブタイピングのための方法 |
| CA3024747A1 (en) * | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3538142A4 (en) * | 2016-11-11 | 2020-07-01 | Medimmune, LLC | ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| NZ759442A (en) | 2017-06-01 | 2024-07-05 | Cytomx Therapeutics Inc | Activatable anti-pdl1 antibodies, and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| EA202092043A1 (ru) * | 2018-03-08 | 2020-12-28 | Астразенека Аб | Композиции и способы для лечения рака легкого на поздней стадии |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| JP7487558B2 (ja) | 2020-05-25 | 2024-05-21 | 船井電機株式会社 | 面光源装置および表示装置 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| TW202325738A (zh) * | 2021-10-29 | 2023-07-01 | 美商昂科Ｃ４公司 | 抗ctla-4抗體給藥方案 |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| AU2011203119C1 (en) * | 2005-05-09 | 2018-06-14 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907424T3 (en) * | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2008100562A2 (en) * | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| DK3279215T3 (da) | 2009-11-24 | 2020-04-27 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| CN102000947B (zh) * | 2010-10-14 | 2012-06-06 | 沈阳飞机工业（集团）有限公司 | 两半轴瓦的铣切加工方法 |
| KR20180019247A (ko) | 2010-11-05 | 2018-02-23 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| CN101975831B (zh) * | 2010-11-25 | 2012-09-05 | 中国检验检疫科学研究院 | 高效液相色谱法测定化妆品中苯酚磺酸锌的方法 |
| US8609625B2 (en) * | 2011-06-24 | 2013-12-17 | Taipei Veterans General Hospital | Method for enhancing immune response in the treatment of infectious and malignant diseases |
| US9863935B2 (en) * | 2012-05-08 | 2018-01-09 | H. Lee Moffitt Cancer And Research Institute, Inc. | Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy |
| WO2013172926A1 (en) * | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| US9107960B2 (en) * | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| SG11201506727RA (en) * | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
| RU2702332C2 (ru) * | 2014-05-13 | 2019-10-08 | Медиммьюн Лимитед | Антитела к в7-н1 и к ctla-4 для лечения немелкоклеточного рака легкого |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| SG11201703332SA (en) * | 2014-11-10 | 2017-05-30 | Medimmune Ltd | Binding molecules specific for cd73 and uses thereof |
| AU2016249395B2 (en) * | 2015-04-17 | 2022-04-07 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-PD-1 antibody and another antibody |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
-
2015
- 2015-05-12 RU RU2016148645A patent/RU2702332C2/ru active
- 2015-05-12 PL PL15722195T patent/PL3142751T3/pl unknown
- 2015-05-12 AU AU2015260962A patent/AU2015260962B2/en active Active
- 2015-05-12 JP JP2016567088A patent/JP6648038B2/ja active Active
- 2015-05-12 EP EP15722195.3A patent/EP3142751B1/en active Active
- 2015-05-12 LT LTEP15722195.3T patent/LT3142751T/lt unknown
- 2015-05-12 SG SG10201810108PA patent/SG10201810108PA/en unknown
- 2015-05-12 KR KR1020237040802A patent/KR20230165876A/ko active Application Filing
- 2015-05-12 RS RS20191070A patent/RS59134B1/sr unknown
- 2015-05-12 HU HUE15722195A patent/HUE045965T2/hu unknown
- 2015-05-12 PT PT157221953T patent/PT3142751T/pt unknown
- 2015-05-12 KR KR1020167031692A patent/KR102333658B1/ko active IP Right Grant
- 2015-05-12 ME MEP-2019-231A patent/ME03493B/me unknown
- 2015-05-12 GB GB1508097.1A patent/GB2531094A/en not_active Withdrawn
- 2015-05-12 WO PCT/EP2015/060523 patent/WO2015173267A1/en active Application Filing
- 2015-05-12 SI SI201530857T patent/SI3142751T1/sl unknown
- 2015-05-12 KR KR1020217038830A patent/KR20210149870A/ko not_active Application Discontinuation
- 2015-05-12 US US14/710,101 patent/US10232040B2/en active Active
- 2015-05-12 DK DK15722195.3T patent/DK3142751T3/da active
- 2015-05-12 KR KR1020227040764A patent/KR20220162844A/ko active Application Filing
- 2015-05-12 CN CN202110380316.8A patent/CN113230398A/zh active Pending
- 2015-05-12 CN CN201580024117.6A patent/CN106456756B/zh active Active
- 2015-05-12 ES ES15722195T patent/ES2749098T3/es active Active
- 2015-05-12 BR BR122023025321-3A patent/BR122023025321A2/pt unknown
- 2015-05-12 EP EP19190351.7A patent/EP3603748A1/en active Pending
- 2015-05-12 MX MX2016014189A patent/MX2016014189A/es active IP Right Grant
- 2015-05-12 CA CA2947471A patent/CA2947471A1/en active Pending
- 2015-05-12 SG SG11201609285SA patent/SG11201609285SA/en unknown
- 2015-05-13 TW TW104115327A patent/TWI707692B/zh active
- 2015-05-13 TW TW110144264A patent/TWI780994B/zh active
- 2015-05-13 TW TW109134952A patent/TW202123967A/zh unknown
-
2016
- 2016-10-26 IL IL248528A patent/IL248528B/en active IP Right Grant
-
2019
- 2019-01-24 US US16/256,022 patent/US11446377B2/en active Active
- 2019-08-09 HR HRP20191449 patent/HRP20191449T1/hr unknown
- 2019-10-03 CY CY20191101034T patent/CY1122642T1/el unknown
-
2020
- 2020-01-15 JP JP2020004032A patent/JP2020090509A/ja active Pending
- 2020-08-04 IL IL276481A patent/IL276481B/en unknown
- 2020-09-10 AU AU2020230309A patent/AU2020230309B2/en active Active
-
2021
- 2021-03-10 JP JP2021037883A patent/JP2021098734A/ja active Pending
-
2022
- 2022-08-09 US US17/818,546 patent/US20230115328A1/en active Pending
-
2023
- 2023-01-25 JP JP2023009115A patent/JP7519477B2/ja active Active
- 2023-07-04 AU AU2023204286A patent/AU2023204286A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276481B (en) | Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer | |
| HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
| HK1247578A1 (zh) | 用於治療非小細胞肺癌的組合抗pd-l1和抗ctla4抗體 | |
| HK1251862A1 (zh) | 治療癌症的方法和組合物 | |
| EP3265113A4 (en) | ANTI-LRB ANTIBODIES AND THEIR USE FOR THE DETECTION AND TREATMENT OF CANCER | |
| PT3063173T (pt) | Anticorpos anti-cd38 específicos para o tratamento de cancros humanos | |
| HK1245804A1 (zh) | 用於治療pvns的抗csf1r抗體 | |
| HK1252370A1 (zh) | 用於治療非小細胞肺癌的治療方法和組合物 | |
| EP3177292A4 (en) | Compounds and methods for treating cancer | |
| TWI560201B (en) | Bi-specific antibodies for treating cancer | |
| IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
| EP3191128A4 (en) | Uses of anti-her3 antibodies for treating cancer | |
| IL262656A (en) | Nanoliposomal irinotecan for use in the treatment of small cell lung cancer | |
| IL250507B (en) | Anti-ck8 antibodies for use in cancer treatment | |
| IL255079A0 (en) | Methods of treating lung cancer | |
| EP3119426A4 (en) | Methods and materials for treating cancer | |
| EP3119427A4 (en) | Methods and materials for treating cancer | |
| EP3240566A4 (en) | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy | |
| EP3273970A4 (en) | Methods and materials for treating cancer | |
| EP3538142A4 (en) | ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | |
| GB201411393D0 (en) | Agents and methods for determining colorectal cancer status | |
| EP3177637B8 (en) | Kpv for treating colorectal cancer and ibd | |
| GB201414904D0 (en) | Materials and methods for treating cancer |